- Stocks
- Pharma & Healthcare
- Piramal Pharma
Piramal Pharma share price
NSE: PPLPHARMAPharma & HealthcareDrug Manufacturers - Specialty & Generic
Piramal Pharma at a glance
Piramal Pharma (NSE: PPLPHARMA) closed at ₹198.24 on 21 Oct 2026, up 2.19% on the day. With a market capitalisation of ₹26,393 Cr, it ranks 302nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 25× trailing earnings, against a return on equity of −4.0% in FY26. Over the past year the share price has risen 0.4%. Its 52-week range is ₹132.30 (23 Mar 2026) to ₹231.93 (8 Sep 2026); the last close is 14.5% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹2,270 Cr (+17.4% year on year) and net profit −₹89 Cr, on a consolidated basis. Promoters held 34.80% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹26,393 CrRank 302 on NSE
- P/E (trailing)
- 25×
- Price to book
- 2.22×FY26
- EPS (TTM)
- −₹2.37to Q1 FY27
- ROE
- −4.0%FY26
- ROCE
- 2.3%FY26
- Debt to equity
- 0.67FY26
- Net profit margin
- −4.3%FY26
- Book value / share
- ₹61.50FY26
- 52-week high
- ₹231.938 Sep 2026
- 52-week low
- ₹132.3023 Mar 2026
- 1-year return
- +0.4%
- RSI (14-day)
- 46
Returns to 21 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +2.19% | +1.1% | −5.2% | +7.0% | +0.4% |
Piramal Pharma quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2,242 Cr | ₹2,204 Cr | ₹2,754 Cr | ₹1,934 Cr | ₹2,044 Cr | ₹2,140 Cr | ₹2,752 Cr | ₹2,270 Cr |
| Revenue YoY | +17.3% | +12.5% | +7.9% | −0.9% | −8.8% | −2.9% | −0.1% | +17.4% |
| Net profit | ₹5 Cr | −₹13 Cr | ₹137 Cr | −₹100 Cr | −₹114 Cr | −₹146 Cr | −₹22 Cr | −₹89 Cr |
| Net profit YoY | — | — | +53.8% | — | −2,239.0% | — | −116.3% | — |
| Net margin | 0.2% | −0.6% | 5.0% | −5.2% | −5.6% | −6.8% | −0.8% | −3.9% |
| EPS | ₹0.17 | ₹0.03 | ₹1.16 | −₹0.62 | −₹0.75 | −₹1.03 | −₹0.07 | −₹0.52 |
Piramal Pharma financials
| Item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | ₹6,559 Cr | ₹7,082 Cr | ₹8,171 Cr | ₹9,151 Cr | ₹8,869 Cr |
| Operating profit | ₹441 Cr | −₹168 Cr | ₹183 Cr | ₹342 Cr | −₹37 Cr |
| Net profit | ₹317 Cr | −₹241 Cr | −₹42 Cr | ₹18 Cr | −₹383 Cr |
| EPS (₹) | ₹3.00 | −₹2.00 | ₹0.00 | ₹1.00 | −₹2.00 |
| Cash from operations | ₹766 Cr | ₹484 Cr | ₹1,005 Cr | ₹892 Cr | ₹1,653 Cr |
| Total debt | ₹2,622 Cr | ₹3,384 Cr | ₹2,484 Cr | ₹3,214 Cr | ₹4,300 Cr |
| Shareholders' equity | ₹6,697 Cr | ₹6,774 Cr | ₹7,911 Cr | ₹8,125 Cr | ₹8,163 Cr |
Piramal Pharma shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 34.95% | 34.86% | 34.86% | 34.86% | 34.86% | 34.80% |
| Foreign institutions | 31.49% | 30.86% | 30.27% | 29.66% | 30.18% | 12.52% |
| Domestic institutions | 14.78% | 14.26% | 14.89% | 15.69% | 15.61% | 14.57% |
| Non-institutions | 18.44% | 19.45% | 19.47% | 19.35% | 19.01% | 37.63% |
Piramal Pharma vs peers
The listed Pharma & Healthcare companies nearest to Piramal Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| WOCKPHARMAWockhardt | ₹1,905.90 | +0.05% | +37.3% | ₹30,969 Cr | 146 | 4.3% |
| SAILIFESai Life Sciences | ₹1,377.60 | −0.96% | +59.3% | ₹29,245 Cr | 83.9 | 8.0% |
| KIMSKrishna Institute of Medical Sciences | ₹672.75 | −0.47% | −5.5% | ₹28,256 Cr | 112.1 | 18.0% |
| PPLPHARMAPiramal Pharma | ₹198.24 | +2.19% | +0.4% | ₹26,393 Cr | 25 | −4.0% |
| NEULANDLABNeuland Laboratories | ₹18,745.00 | −2.57% | +15.6% | ₹24,050 Cr | 65.9 | 19.4% |
| RUBICONRubicon Research | ₹1,433.20 | −3.30% | — | ₹23,703 Cr | 93.9 | 19.1% |
| PGHHProcter Gamble | ₹7,006.50 | −1.46% | −50.3% | ₹22,744 Cr | 26.5 | 62.3% |
Ask anything about Piramal Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against PPLPHARMA's own history. Try: “Why has PPLPHARMA moved over the last three months?” · “Backtest a 50-day moving-average crossover on PPLPHARMA over five years” · “Compare PPLPHARMA with WOCKPHARMA on margins and valuation”
Frequently asked questions about Piramal Pharma
What is the share price of Piramal Pharma today?
Piramal Pharma (NSE: PPLPHARMA) last closed at ₹198.24 on 21 Oct 2026. Its 52-week high is ₹231.93 and its 52-week low is ₹132.30.
What is the market cap of Piramal Pharma?
Piramal Pharma's market capitalisation is ₹26,393 Cr (₹26,393 Cr) at the 21 Oct 2026 close, ranking 302nd among the NSE companies Pivot tracks.
What is the P/E ratio of Piramal Pharma?
Piramal Pharma trades at a trailing P/E of 25. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 93.9.
What is the ROE and ROCE of Piramal Pharma?
Return on equity was −4.0% in FY26 and return on capital employed was 2.3% in FY26 (consolidated figures).
Is Piramal Pharma a debt-free company?
No. Piramal Pharma's debt-to-equity ratio was 0.67 in FY26, with total debt of ₹4,300 Cr.
What were Piramal Pharma's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Piramal Pharma reported revenue of ₹2,270 Cr, +17.4% year on year, and net profit of −₹89 Cr.
How has Piramal Pharma stock performed over the last year?
Piramal Pharma's share price has risen 0.4% over the past year, +7.0% over three months and −5.2% over one month, to the 21 Oct 2026 close.
What is the shareholding pattern of Piramal Pharma?
As of 30 Jun 2026: promoters 34.80%, foreign institutions 12.52%, domestic institutions 14.57%, non-institutions 37.63%.
Who are Piramal Pharma's competitors?
The listed Pharma & Healthcare companies closest to Piramal Pharma by market cap are Wockhardt, Sai Life Sciences, Krishna Institute of Medical Sciences, Neuland Laboratories, Rubicon Research and Procter Gamble.
Is Piramal Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Piramal Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on PPLPHARMA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026 (returns and ratios at the 21 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with P · all NSE stocks · this page as text